Alprolix eftrenonacog alfa regulatory update

The European Commission approved Alprolix eftrenonacog alfa from Biogen for the treatment and prophylaxis of bleeding in patients with hemophilia B. Alprolix is approved in the U.S., Canada, Japan, Australia and New Zealand. It is a recombinant fusion protein consisting of human coagulation Factor IX attached to the Fc domain of human IgG1. ...